Drug firm Alkem Labs Ltd today said its Daman manufacturing plant has obtained the Establishment Inspection Report (EIR) from US health regulator USFDA.
"The USFDA has issued an Establishment Inspection Report for its Daman manufacturing facility which was inspected by the USFDA in September 2016," Alkem Labs said in a BSE filing.
USFDA released a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
The stock of Alkem Labs was trading at Rs 1633.60, up 1.56 per cent, from its previous close on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
